The kynurenine pathway of tryptophan degradation generates several neuroactive
compounds. Of those, kynurenic acid is an N-methyl-d-aspartate (NMDA) and alpha7 nicotinic …

Background: Accumulating evidence indicates that schizophrenia is associated with brain
immune activation. While a number of reports suggest increased cytokine levels in patients …

In recent years progress in the field of schizophrenia research has led to the suggestion that
dopamine only plays an intermediary role in the pathophysiology of the disease and that the …

BACKGROUND: Recent studies show that endogenous levels of kynurenic acid (KYNA) are
increased in the cerebrospinal fluid of schizophrenic patients. Prepulse inhibition (PPI) of …

Considerable data relate major depressive disorder (MDD) with aberrant immune system
functioning. Pro-inflammatory cytokines facilitate metabolism of tryptophan along the …

Several studies suggest a role for kynurenic acid (KYNA) in the pathophysiology of schizophrenia.
It has been proposed that increased brain KYNA levels in schizophrenia result from a …

Background Neuroinflammation is increasingly recognized as contributing to the
pathogenesis of depression. Key inflammatory markers as well as kynurenic acid (KYNA) and …

Clozapine has a remarkable efficacy in treatment-resistant schizophrenia and is one of the
most effective antipsychotic drugs used today. The clinical effects of clozapine are suggested …

Background: Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF)
concentrations of the endogenous N-methyl-d-aspartate receptor antagonist kynurenic …

Metabolites of the kynurenine pathway of tryptophan degradation, in particular, the N-Methyl-d-aspartic
acid receptor antagonist kynurenic acid (KYNA), are increasingly recognized as …